Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
Holding NEO?
Track your performance easily
Earnings Data
Report Date
Feb 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.03Last Year’s EPS
0.03Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2018
|% Change Since: 0.50%
|Next Earnings Date:Jul 24, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, improved profitability, and successful product launches. However, challenges such as a decline in Pharma revenue and increased legal expenses were noted. Overall, the company's financial performance and strategic initiatives indicate a positive outlook.Company Guidance
During NeoGenomics' Q3 2024 earnings call, the company provided updated guidance reflecting strong financial performance. Total revenues increased by 10% year-over-year to $168 million, with the clinical business revenues growing by 14%. Total test volume rose by 9%, and revenue per test improved by 5%. NeoGenomics reported a 305% improvement in adjusted EBITDA, reaching $13 million, marking the fifth consecutive quarter of positive adjusted EBITDA. Additionally, the company increased its adjusted EBITDA guidance for the year to $37 million to $40 million, an over 1,000% growth from last year. The call highlighted significant organic volume growth, particularly in next-generation sequencing (NGS), which grew by 26% and now represents 31% of clinical volume and revenue.Record Revenue Growth
Total revenues grew 10% year-over-year, with clinical business revenues increasing by 14% compared to the third quarter of last year, marking a record quarter in total test volume and revenues.
NGS Segment Expansion
NGS (Next-Generation Sequencing) grew by 26%, now representing 31% of total clinical volume and revenue.
Improved Profitability
Adjusted EBITDA improved by $10 million or 305% from the prior year, marking the fifth consecutive quarter of positive adjusted EBITDA.
Operational Efficiency
Gross margin improved by 355 basis points, with improved turnaround time by 10% compared to Q3 of 2023.
Innovative Product Launches
Launch of Neo AML Express and conditional approval for Neo Comprehensive Solid Tumor in New York State.
Strong Cash Position
Ended the third quarter with $388 million in cash and marketable securities, maintaining a strong liquidity profile.
---
NEO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NEO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $14.14 | $14.93 | +5.59% |
| Jul 29, 2024 | $14.64 | $17.27 | +17.96% |
| Apr 30, 2024 | $15.22 | $13.92 | -8.54% |
| Feb 20, 2024 | $14.70 | $16.48 | +12.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does NeoGenomics (NEO) report earnings?
NeoGenomics (NEO) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
What is NeoGenomics (NEO) earnings time?
NeoGenomics (NEO) earnings time is at Feb 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NEO EPS forecast?
NEO EPS forecast for the fiscal quarter 2024 (Q4) is 0.03.
---
